Concordancia del FRAX México con y sin el valor de la densidad mineral ósea en la evaluación del riesgo de fractura en la práctica clínica diaria

Nelson, 2010, Screening for osteoporosis: An update for the U. S. Preventive Services Task Force, Ann Intern Med, 153, 99, 10.7326/0003-4819-153-2-201007200-00262 Kanis, 2016, A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation, Arch Osteoporos, 11, 25, 10.1007/s11657-016-0278-z Kanis, 2015, FRAX and fracture prediction without bone mineral density, Climacteric, 18, 2, 10.3109/13697137.2015.1092342 Sanders, 2006, Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?, Bone, 38, 694, 10.1016/j.bone.2005.06.004 Wainwright, 2005, Hip fracture in women without osteoporosis, J Clin Endocrinol Metab, 90, 2787, 10.1210/jc.2004-1568 Johansson, 2009, BMD, clinical risk factors and their combination for hip fracture prevention, Osteoporos Int, 20, 1675, 10.1007/s00198-009-0845-x Kanis, 2012, FRAX® with and without bone mineral density, Calcif Tissue Int, 90, 1, 10.1007/s00223-011-9544-7 Siris, 2014, The clinical diagnosis of osteoporosis: A position statement from the National Bone Health Alliance Working Group, Osteoporos Int, 25, 1439, 10.1007/s00198-014-2655-z Schousboe, 2015, Diagnostic criteria for osteoporosis should not be expanded, Lancet Diabetes Endocrinol, 3, 236, 10.1016/S2213-8587(15)00050-9 Clark, 2013, Epidemiology of osteoporosis in Mexico. Present and future directions, Rev Invest Clin, 65, 183 McClung, 2009, The clinical and epidemiologic consequences of redefining treatment criteria: Who should be treated?, Salud Publica Mex, 51, S46, 10.1590/S0036-36342009000700008 Hans, 2011, Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice, J Clin Densitom, 14, 171, 10.1016/j.jocd.2011.05.007 Lewiecki, 2011, Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®, J Clin Densitom, 14, 226, 10.1016/j.jocd.2011.05.017 Egsmose, 2015, FRAX fracture risk in women with a recent fracture of the distal forearm: Agreement between assessments with and without bone mineral density and impact of measurement side in the individual patient, Clin Rheumatol, 34, 1265, 10.1007/s10067-014-2640-0 Kanis, 2013, Standardising the descriptive epidemiology of osteoporosis: Recommendations from the Epidemiology and Quality of Life Working Group of IOF, Osteoporos Int, 24, 2763, 10.1007/s00198-013-2413-7 Olmez Sarikaya, 2014, Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey, Clin Rheumatol, 33, 1785, 10.1007/s10067-014-2491-8 Bastos-Silva, 2016, Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data, Arch Osteoporos, 11, 16, 10.1007/s11657-015-0255-y Leslie, 2014, Comparison between various fracture risk assessment tools, Osteoporos Int, 25, 1, 10.1007/s00198-013-2409-3 Kanis, 2016, SIGN guidelines for Scotland: BMD versus FRAX versus QFracture, Calcif Tissue Int, 98, 417, 10.1007/s00223-015-0092-4 Gadam, 2013, Frax prediction without BMD for assessment of osteoporotic fracture risk, Endocr Pract, 19, 780, 10.4158/EP12416.OR Leslie, 2012, Fracture risk assessment without bone density measurement in routine clinical practice, Osteoporos Int, 23, 75, 10.1007/s00198-011-1747-2 Ilias, 2012, Use of the FRAX calculator with and without bone mineral density in Greek women, Hormones (Athens), 11, 222, 10.14310/horm.2002.1352 Gómez-Vaquero, 2012, The activity of a Spanish bone densitometry unit revisited under the point of view of FRAX, Reumatol Clin, 8, 179, 10.1016/j.reuma.2012.02.003 Kim, 2015, Validation of FRAX without BMD: An age-related analysis of the Fifth Korean National Health and Nutrition Examination Survey (KNHANES V-1, 2010), Bone, 75, 27, 10.1016/j.bone.2015.02.013 Hamdy, 2009, Variance in 10-year fracture risk calculated with and without T-scores in select subgroups of normal and osteoporotic patients, J Clin Densitom, 12, 158, 10.1016/j.jocd.2008.12.003 Marques, 2015, The accuracy of osteoporotic fracture risk prediction tools: A systematic review and meta-analysis, Ann Rheum Dis, 74, 1958, 10.1136/annrheumdis-2015-207907 Fraser, 2011, Fracture prediction and calibration of a Canadian FRAX® tool: A population-based report from CaMos, Osteoporos Int, 22, 829, 10.1007/s00198-010-1465-1 Naranjo, 2015, [Spanish FRAX®: Pathing the way through walking] Spanish, Med Clin (Barc), 144, 21, 10.1016/j.medcli.2014.01.011 Perez Edo, 2011, [2011 up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis] Spanish, Reumatol Clin, 7, 357 Kanis, 2009, Approaches to the targeting of treatment for osteoporosis, Nat Rev Rheumatol, 5, 425, 10.1038/nrrheum.2009.139 Azagra, 2015, [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population] Spanish, Med Clin (Barc), 144, 1, 10.1016/j.medcli.2013.11.014 Kyriakos, 2016, A comparative study between the implementation of the FRIDEX calibration and the NOGG guideline in the management of osteoporosis in routine clinical practice, Reumatol Clin Kanis, 2013, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos Int, 24, 23, 10.1007/s00198-012-2074-y Ott, 2013, What should be the interval between bone density screenings?, Cleve Clin J Med, 80, 240, 10.3949/ccjm.80a.12166 Lewiecki, 2012, Bone density testing intervals and common sense, Curr Osteoporos Rep, 10, 217, 10.1007/s11914-012-0111-6